Clarifications regarding the authority and role of FDA in drug approval.
With great concern, we read the editorial entitled, "FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression" by Drs. Klintmalm, Kaplan, and Kirk.1 The editorial reflects a misunderstanding of FDA's role and authority, as well as of the feasibility of randomized controlled clinical trials (RCTs) in lung transplantation.